Login to Your Account



Amgen Makes History with $762M Off-Label Settlement

By Mari Serebrov
Washington Editor

Wednesday, December 19, 2012
regulatory.jpg

In what's being called the largest settlement ever for a biotech company, Amgen Inc. finalized a $612 million agreement Tuesday to resolve federal civil claims stemming from 10 whistleblower suits alleging off-label marketing of several of its top-selling drugs.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription